EICHORCondition: Atopic Dermatitis · Sponsor: Amgen
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Cahaba Dermatology and Skin Health Center | Birmingham, Alabama, United States | — |
| Alliance Dermatology and Mohs Center | Phoenix, Arizona, United States | — |
| Anaheim Clinical Trials | Anaheim, California, United States | — |
| First OC Dermatology | Fountain Valley, California, United States | — |
| Kaiser Permanente - Glendale Medical Center | Glendale, California, United States | — |
| Long Beach Research Institute | Long Beach, California, United States | — |
| Kaiser Permanente Los Angeles Medical Center | Los Angeles, California, United States | — |
| Dermatology Research Associates | Los Angeles, California, United States | — |
| Cura Clinical Research | Sherman Oaks, California, United States | — |
| IMMUNOe Research Centers | Centennial, Colorado, United States | — |
| Skin Care Research Incorporated | Boca Raton, Florida, United States | — |
| Palm Beach Dermatology Group | Delray Beach, Florida, United States | — |
+ 190 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05398445